AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20959776 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIF+PLF
Number of subjects: 95
Study 20959776 — intervention group
Group type: COMPARATOR
Intervention: PLF alone
Number of subjects: 95
Study 17380472 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis
Number of subjects: 0
Study 17380472 — intervention group
Group type: COMPARATOR
Intervention: Mid-trimester amniocentesis
Number of subjects: 0
Study 17380472 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal testing for congenital toxoplasmosis
Number of subjects: 0
Study 15650632 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic subtotal gastrectomy (LG)
Number of subjects: 59
Study 15650632 — intervention group
Group type: COMPARATOR
Intervention: Open subtotal gastrectomy (OG)
Number of subjects: 59
Study 12192322 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical pancreaticoduodenectomy (extended)
Number of subjects: 294
Study 12192322 — intervention group
Group type: COMPARATOR
Intervention: Standard pancreaticoduodenectomy
Number of subjects: 294
Study 10439568 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 74
Study 10439568 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 74
Study 10439568 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 74
Study 7557571 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse bran (15 g)
Number of subjects: 12
Study 7557571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine bran (15 g)
Number of subjects: 12
Study 7557571 — intervention group
Group type: COMPARATOR
Intervention: Control (no bran)
Number of subjects: 12
Study 7557571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bran types
Number of subjects: 12
Study 2162633 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH group (7.5 ml/kg body weight within 30 min during substitution with 6% HES 200/0.5)
Number of subjects: 20
Study 2162633 — intervention group
Group type: COMPARATOR
Intervention: Control group (without hemodilution)
Number of subjects: 20
Study 2162633 — intervention group
Group type: EXPERIMENTAL
Intervention: ANH group
Number of subjects: 20
Study 2162633 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7410734 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude estimation ratings of symptom pathology
Number of subjects: 129
Study 7410734 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex interaction
Number of subjects: 129
Study 7410734 — intervention group
Group type: COMPARATOR
Intervention: Sex alone
Number of subjects: 129
Study 30336227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudging with increased saliency of healthiness (not related to calorie content)
Number of subjects: 0
Study 30336227 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated consumption of a healthy meal described as low in caloric content
Number of subjects: 0
Study 30336227 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated healthy meals not portrayed to be low in calories
Number of subjects: 0
Study 27458066 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI)
Number of subjects: 89
Study 27458066 — intervention group
Group type: COMPARATOR
Intervention: Control group (anti-infection, reducing sputum, and support therapy)
Number of subjects: 89
Study 25467927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral therapy (lomustine, cyclophosphamide, etoposide)
Number of subjects: 131
Study 25467927 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy (cyclophosphamide, doxorubicin, vincristine - CAV)
Number of subjects: 131
Study 23727060 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group (20-minute sessions once per week for 12 weeks)
Number of subjects: 44
Study 23727060 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy group (1-hour sessions once per week for 12 weeks)
Number of subjects: 44
Study 21561392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 138
Study 21561392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 19906163 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (20% wt/vol aminolevulinic acid hydrochloride)
Number of subjects: 91
Study 19906163 — intervention group
Group type: COMPARATOR
Intervention: CO(2) laser
Number of subjects: 91
Study 19906163 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 91
Study 17097185 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm 1 (increments of at least 10%, but not exceeding 4U)
Number of subjects: 2442
Study 17097185 — intervention group
Group type: COMPARATOR
Intervention: Algorithm 2 (1‐6U increments)
Number of subjects: 2442
Study 17097185 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm 1
Number of subjects: 2442
Study 17097185 — intervention group
Group type: COMPARATOR
Intervention: Algorithm 2
Number of subjects: 2442
Study 15087974 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 0
Study 15087974 — intervention group
Group type: COMPARATOR
Intervention: Casting
Number of subjects: 0
Study 11586091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed paclitaxel at 15 mg/m2
Number of subjects: 23
Study 11586091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed paclitaxel at 20 mg/m2
Number of subjects: 23
Study 11586091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed paclitaxel at 25 mg/m2
Number of subjects: 23
Study 11586091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-dose paclitaxel and radiation
Number of subjects: 23
Study 10211011 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 ketoprofen i.v.
Number of subjects: 220
Study 10211011 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg kg‐1 ketoprofen i.v.
Number of subjects: 220
Study 10211011 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg kg‐1 ketoprofen i.v.
Number of subjects: 220
Study 10211011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 7933031 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography
Number of subjects: 67
Study 7933031 — intervention group
Group type: COMPARATOR
Intervention: Color Doppler Imaging (CDI)
Number of subjects: 67
Study 3411660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin therapy
Number of subjects: 47
Study 3411660 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltose tetrapalmitate
Number of subjects: 47
Study 3411660 — intervention group
Group type: COMPARATOR
Intervention: Control (transurethral resection only)
Number of subjects: 47
Study 31820874 — intervention group
Group type: EXPERIMENTAL
Intervention: Orogastric tube guide (GTG)
Number of subjects: 151
Study 31820874 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'blind' technique (CONV)
Number of subjects: 151
Study 30458521 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Sound Amplification Products (PSAPs)
Number of subjects: 25
Study 30458521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Aids
Number of subjects: 25
Study 30458521 — intervention group
Group type: COMPARATOR
Intervention: Unaided Listening
Number of subjects: 25
Study 28088218 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 190
Study 28088218 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 190
Study 26330658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potassium diet
Number of subjects: 0
Study 26330658 — intervention group
Group type: COMPARATOR
Intervention: High-salt, low-potassium diet
Number of subjects: 0
Study 24304724 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 100
Study 24304724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 100
Study 24304724 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Lapatinib
Number of subjects: 100
Study 21167404 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum sunscreen
Number of subjects: 25
Study 21167404 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 25
Study 21167404 — intervention group
Group type: COMPARATOR
Intervention: Untreated area
Number of subjects: 25
Study 21167404 — intervention group
Group type: COMPARATOR
Intervention: Age of disease onset
Number of subjects: 25
Study 19061735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive rehabilitation (n=34)
Number of subjects: 68
Study 19061735 — intervention group
Group type: COMPARATOR
Intervention: Standard neurorehabilitation (n=34)
Number of subjects: 68
Study 17251692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional training (FT)
Number of subjects: 15
Study 17251692 — intervention group
Group type: COMPARATOR
Intervention: Strength training (ST)
Number of subjects: 15
Study 14988338 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (10 cm H(2)O)
Number of subjects: 60
Study 14988338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel non-invasive ventilation (IPAP 15 cm H(2)O, EPAP 5 cm H(2)O)
Number of subjects: 60
Study 14988338 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (Control)
Number of subjects: 60
Study 11340683 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin (Mono)
Number of subjects: 98
Study 11340683 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with tobramycin/ceftazidime (Conv)
Number of subjects: 98
Study 9448231 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized flunisolide nasal spray (250 microg, 1 ml, administered three times daily)
Number of subjects: 22
Study 9448231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7960012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ouabain standard or bolus intravenous injections of ouabain
Number of subjects: 0
Study 7960012 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatography of sample extracts
Number of subjects: 0
Study 7960012 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay for ouabain
Number of subjects: 0
Study 3109265 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 21
Study 3109265 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (inhalation of air)
Number of subjects: 21
Study 30258217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two potent bNAbs (3BNC117 and 10-1074) administered at 30 mg kg-1 each
Number of subjects: 7
Study 30258217 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two potent bNAbs (3BNC117 and 10-1074)
Number of subjects: 7
Study 26174907 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic 7-day diary
Number of subjects: 100
Study 26174907 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic continuous diary (Cont A)
Number of subjects: 100
Study 26174907 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic partially continuous diary (Cont B)
Number of subjects: 100
Study 26174907 — intervention group
Group type: COMPARATOR
Intervention: 3-day paper diary
Number of subjects: 100
Study 26174907 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week diary schedules
Number of subjects: 100
Study 24614127 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 8
Study 24614127 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy infants)
Number of subjects: 8
Study 23214246 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm‐EDTMP, injected intravenously at 37.0 MBq/kg body weight
Number of subjects: 55
Study 23214246 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid, administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride
Number of subjects: 55
Study 20068492 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 50
Study 20068492 — intervention group
Group type: EXPERIMENTAL
Intervention: Free weights training
Number of subjects: 50
Study 20068492 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine weights training
Number of subjects: 50
Study 20068492 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine weights + balance training
Number of subjects: 50
Study 20068492 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 18490016 — intervention group
Group type: EXPERIMENTAL
Intervention: Coculture
Number of subjects: 17
Study 18490016 — intervention group
Group type: COMPARATOR
Intervention: Control (non-coculture)
Number of subjects: 17
Study 16081477 — intervention group
Group type: EXPERIMENTAL
Intervention: RhEPO (150 IU kg(‐1) weekly subcutaneous injection; n = 8)
Number of subjects: 15
Study 16081477 — intervention group
Group type: COMPARATOR
Intervention: Control (10 ml sterile saline weekly subcutaneous injection; n = 7)
Number of subjects: 15
Study 12223948 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy
Number of subjects: 697
Study 12223948 — intervention group
Group type: COMPARATOR
Intervention: Timolol + dorzolamide
Number of subjects: 697
Study 10689609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 0
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography recommendation by American physicians
Number of subjects: 532
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of cardiac procedures
Number of subjects: 532
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting period for cardiac procedures
Number of subjects: 532
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist proportion
Number of subjects: 532
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional cardiologist proportion
Number of subjects: 532
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing clinical decisions
Number of subjects: 532
Study 7760576 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography recommendation after adjustment
Number of subjects: 532
Study 2315645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and selenium supplementation (placebo-controlled)
Number of subjects: 0
Study 2315645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 657058 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamicin-ampicillin
Number of subjects: 60
Study 657058 — intervention group
Group type: EXPERIMENTAL
Intervention: tobramycin-cephalothin
Number of subjects: 60
Study 657058 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin-ampicillin
Number of subjects: 60
Study 31116883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) classes conducted twice/week for 1 year
Number of subjects: 180
Study 31116883 — intervention group
Group type: COMPARATOR
Intervention: Health promotion educational classes and social calls (Control)
Number of subjects: 180
Study 26822516 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched meals (1720 mg per day for 12 months)
Number of subjects: 75
Study 26822516 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 75
Study 25462647 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 0
Study 25462647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25462647 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25462647 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal
Number of subjects: 0
Study 25462647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low arousal
Number of subjects: 0
Study 23112272 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 181
Study 23112272 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 181
Study 23112272 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Number of subjects: 181
Study 23112272 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (doses > 50 U)
Number of subjects: 181
Study 23112272 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (doses ≤ 50 U)
Number of subjects: 181
Study 23112272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 20963406 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO with lignocaine
Number of subjects: 160
Study 20963406 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 160
Study 19761837 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg H5N1 influenza vaccine with aluminum hydroxide adjuvant
Number of subjects: 300
Study 19761837 — intervention group
Group type: COMPARATOR
Intervention: 7.5 microg H5N1 influenza vaccine without adjuvant
Number of subjects: 300
Study 19761837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adjuvanted and non-adjuvanted vaccines
Number of subjects: 300
Study 19761837 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with pre-existing antibodies
Number of subjects: 300
Study 19761837 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Number of subjects: 300
Study 17535143 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking with body weight support
Number of subjects: 68
Study 17535143 — intervention group
Group type: COMPARATOR
Intervention: Cycling
Number of subjects: 68
Study 15358996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301
Study 15358996 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study 11675833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 0
Study 11675833 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 0
Study 11675833 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 9875717 — intervention group
Group type: EXPERIMENTAL
Intervention: Music score reading
Number of subjects: 8
Study 9875717 — intervention group
Group type: COMPARATOR
Intervention: Reading text in primary and secondary language
Number of subjects: 8
Study 7989932 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 257
Study 7989932 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy or autologous transplantation (Control)
Number of subjects: 257
Study 2659151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 5 mg intravenously followed by 50 mg orally for six days
Number of subjects: 70
Study 2659151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary polyunsaturated fat
Number of subjects: 18
Study 1246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary changes in lactating women
Number of subjects: 18
Study 1246976 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk
Number of subjects: 18
Study 31721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted least squares fitting using calculated pairwise differences (ΔΔG)
Number of subjects: 0
Study 31721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal experimental design in pair selection
Number of subjects: 0
Study 31721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted optimal designs
Number of subjects: 0
Study 30622224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid sequential injection of fentanyl followed by slow injection of hyperbaric bupivacaine
Number of subjects: 56
Study 30622224 — intervention group
Group type: COMPARATOR
Intervention: Sequential intrathecal injections of fentanyl and hyperbaric bupivacaine at the same rate
Number of subjects: 56
Study 29051399 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigastric port-site retrieval (Group B, n=60)
Number of subjects: 120
Study 29051399 — intervention group
Group type: COMPARATOR
Intervention: Umbilical port-site retrieval (Group A, n=60)
Number of subjects: 120
Study 27063132 — intervention group
Group type: EXPERIMENTAL
Intervention: Original occlusion adjustment method
Number of subjects: 20
Study 27063132 — intervention group
Group type: COMPARATOR
Intervention: Occlusal plane reduction technique
Number of subjects: 20
Study 23883922 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 222
Study 23883922 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m² every 21 days or 35 mg/m² on days 1, 8, and 15 every 28 days
Number of subjects: 222
Study 23883922 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 222
Study 23883922 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 222
Study 21255198 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 100
Study 21255198 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 100
Study 21255198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19506819 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 103
Study 19506819 — intervention group
Group type: COMPARATOR
Intervention: No total mesorectal excision (Control group)
Number of subjects: 103
Study 17342993 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs group (CHG)
Number of subjects: 40
Study 17342993 — intervention group
Group type: COMPARATOR
Intervention: Western medicated group (WMG)
Number of subjects: 40
Study 17342993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WMG and CHG)
Number of subjects: 40
Study 15151580 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially clothed with only disposable nappies and in posturally supported positions (n = 30)
Number of subjects: 59
Study 15151580 — intervention group
Group type: COMPARATOR
Intervention: Naked without postural support (n = 29)
Number of subjects: 59
Study 11355051 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders 1 day before appointments
Number of subjects: 903
Study 11355051 — intervention group
Group type: COMPARATOR
Intervention: Not telephoned (control group)
Number of subjects: 903
Study 11355051 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 903